• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

Test tubes, dropper and capsules
Inflammatory

Immunesensor Therapeutics’ cGAS inhibitor to enter clinic in Australia

Aug. 19, 2024
Immunesensor Therapeutics Inc. has received Human Research Ethics Committee (HREC) approval and clinical trial notification (CTN) clearance by Australia’s Therapeutic Goods Administration (TGA) to initiate a phase I study of IMSB-301, a novel, orally available small-molecule cGAS inhibitor that is being developed for the treatment of inflammatory and autoimmune diseases.
Read More
Cancer

Disruptor of β-catenin pathway contributes to colorectal tumor suppression

Aug. 19, 2024
The hyperactivation of the Wnt/β-catenin signaling pathway plays a central role in the progression and expansion of colorectal cancer (CRC). The suppression of this pathway may contribute to the control of the proliferation, survival and metastasis of CRC.
Read More

Other news to note for Aug. 16, 2024

Aug. 16, 2024
Additional early-stage research and drug discovery news in brief, from: Noxopharm.
Read More

Holiday notice

Aug. 16, 2024
In accordance with the publishing schedule, BioWorld Science was not published on Thursday, Aug. 15, 2024.
Read More
Nephrology

Shanghai Micurx Pharmaceutical identifies peptide-drug conjugates for renal diseases

Aug. 16, 2024
Shanghai Micurx Pharmaceutical Co. Ltd. has discovered peptide-drug conjugates consisting of peptide-targeting kidney cells covalently linked to anti-inflammatory or immunomodulating or nephron-protective drugs through linkers reported to be useful for the treatment of acute kidney injury, nephritis, chronic kidney disease, chronic glomerulonephritis, diabetic nephropathy and systemic lupus erythematosus, among others.
Read More
Cancer

Beijing Tide Pharmaceutical describes new PROTACs for cancer

Aug. 16, 2024
Beijing Tide Pharmaceutical Co. Ltd. has identified proteolysis targeting chimeras (PROTACs) comprising a cereblon E3 ubiquitin ligase binding moiety coupled to tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) targeting agents through linkers reported to be useful for the treatment of cancer.
Read More
Neurology/psychiatric

Shanghai Institute of Organic Chemistry discovers microtubule destabilizers

Aug. 16, 2024
Shanghai Institute of Organic Chemistry has prepared and tested microtubule destabilizers (tubulin polymerization inhibitors) reported to be useful for the treatment of cancer, traumatic brain injury, multiple sclerosis, and Alzheimer’s, Huntington's and Parkinson's disease.
Read More
Cancer

Chinese researchers present new antibody-drug conjugates for HER2-positive cancers

Aug. 16, 2024
Scientists from Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have disclosed antibody-drug conjugates (ADC) comprising antibodies targeting HER2 bound to an eribulin derivative through a linker reported to be useful for the treatment of cancer.
Read More
Cancer

New ACVR1 and ACVRL1 inhibitors reported in Baylor College of Medicine patent

Aug. 16, 2024
Baylor College of Medicine has synthesized activin receptor type-1 (ACVR1; ALK2; ACTR-I) and/or serine/threonine-protein kinase receptor R3 (ACVRL1; ALK1) inhibitors reported to be useful for the treatment of cancer, fibrodysplasia ossificans progressiva (FOP), atherosclerosis and iron deficiency anemia.
Read More
Human natural killer cell
Drug design, drug delivery & technologies

Kytopen receives phase II SBIR grant

Aug. 16, 2024
Kytopen Corp. has received a phase II Small Business Innovation Research (SBIR) grant of $1.6 million from the NIAID/NIH to support preclinical studies of its engineered natural killer (NK) cells. The funding will be used to conduct in vivo preclinical studies, which will be conducted by Charles River Laboratories
Read More
Previous 1 2 … 330 331 332 333 334 335 336 337 338 … 17776 17777 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 7, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 7, 2025.
  • U.S. Capitol building, Washington D.C.

    House passes H.R. 1, restoring R&D tax cuts

    BioWorld MedTech
    The House of Representatives passed H.R. 1, also known as One Big Beautiful Bill, which will restore personal income tax cuts that expired in 2022. However, the...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe